Ibere Pharmaceuticals
IBER
New York Stock Exchange10.18
USD
-0.03
- -
CIK
0001835205
CUSIP
G46843101
Return %
Stock
S&P500
1Y
3.77
26.53
3Y
5.49
76.60
5Y
5.49
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Osagie O. Imasogie
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 2005 Market Street Philadelphia PA United States of America 19103
- CIK
- 0001835205
- Website
- iberepharma.com
- Similar Companies
- Business
- Ibere Pharmaceuticals (NYSE: IBER) operates as a blank check company whose principal business purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting opportunities in the pharmaceutical and life sciences industries; it currently conducts no significant operations and generates no revenues. The company, a Cayman Islands exempted corporation, was incorporated in 2020 and maintains its headquarters at 2005 Market Street, Suite 2030, Philadelphia, Pennsylvania. In March 2021, Ibere Pharmaceuticals completed an initial public offering raising $138 million through the sale of 13.8 million units at $10 each on the New York Stock Exchange; however, it failed to complete an initial business combination by the deadline, leading to the redemption of all outstanding public shares in March 2023 at approximately $10.17 per share and subsequent dissolution of the entity. As of late 2025, the ticker IBER reflects no active pharmaceutical products, services, manufacturing, or ongoing business segments, with recent stock data indicating a market capitalization around $170-175 million but continued lack of operations or revenue.
IberAmerican Responds to Recent Promotional Activity Pursuant to OTC Markets' Request
Cboe Canada Continues to Fuel the Innovation Economy With Public Launch of IberAmerican Lithium
Ibere Pharmaceuticals Receives Expected NYSE Notice Regarding Delayed Quarterly Report